skip to content
  1. Home
  2. >
  3. Questions
  4. >
  5. LLY: I hold HHL in my RRIF which is primarily focused on income. [Eli Lilly and Company]
You can view 2 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I hold HHL in my RRIF which is primarily focused on income. I am considering switching HHL to
HHLE. This would increase my income by approximately 30% on this money and allow me to keep the same list of healthcare stocks. Does this make sense; any downsides ; am I missing anything?

As an aside , I am at breakeven with HHL as the sector is under pressure from Trump and also United Healthcare has dampened the sector. But with Trump wanting lower drug prices , the companies will be going overseas to compensate for lower US revenue as witnessed by Eli Lilly raising international prices for Mounjaro.
Thanks .Derek
Asked by Derek on August 20, 2025
5i Research Answer:

HHLE is at the moment significantly smaller, but likely big enough at $70M, and we would expect it to grow. The main difference here is leverage. HHLE uses 25% leverage. This of course enhances returns but also can add to risk. We would be OK with a switch only on the condition that a risk-tolerant investor understands this use of leverage. The 'go outside the US' makes sense, but also US companies are starting to price in weak sentiment. It may take time, but there is still upside potential for the sector, and any good news might have an amplified positive impact since sentiment and valuations are so low. 

Authors of this answer, directors, partners and/or officers of 5i Research and/or affiliated companies have a financial or other interest in UNH.